HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on Anixa Biosciences (NASDAQ:ANIX) and maintained a $12 price target.
July 12, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences (NASDAQ:ANIX) has had its 'Buy' rating reiterated by HC Wainwright & Co. with a maintained price target of $12.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $12 indicates the firm's continued confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100